Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial
SRZN•The FDA cleared Surrozen’s IND for SZN-8141, an intravitreal diabetic macular edema candidate combining a Wnt agonist with a VEGF antagonist. First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026, and the milestone is expected to trigger a second private-placement closing raising about $95.1 million in gross proceeds.
1. IND clearance and trial timing
The FDA cleared Surrozen’s IND for SZN-8141, an intravitreal diabetic macular edema candidate combining a Wnt agonist with a VEGF antagonist. First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026.
2. Private placement milestone
The milestone is expected to trigger a second closing of Surrozen’s March 2025 private placement, which is expected to raise about $95.1 million in gross proceeds.
